ESMO 2021: Pembrolizumab as monotherapy for first-line treatment of non-clear cell kidney cancer

Non-clear cell RCC is about 20-25% of all RCC diagnoses and usually has worse survival outcomes than clear cell RCC. Both cabozantinib and immune checkpoint inhibitors have been shown to help patients with non-clear cell RCC. KEYNOTE-427 is a phase 2 study that looked at the treatment of people with RCC with pembrolizumab as their […]

read more

ESMO 2021: Pembrolizumab as monotherapy for first-line treatment of kidney cancer

KEYNOTE-427 is an open-label, single-arm, phase II study to look at the effectiveness of pembrolizumab as a first-line treatment for people with advanced clear cell RCC. At ESMO this year, updated efficacy, and safety results after a minimum follow-up of 41 months were presented. This study looked at the treatment of people with RCC with […]

read more

ESMO 2021: Pembrolizumab as adjuvant therapy

Adjuvant therapy is medication that is given in addition to surgery to try to prevent the cancerĀ from coming back. Adjuvant therapy can be used to kill any remaining microscopic cancer cells, or it can control the growth of any remaining cancer. Nephrectomy is the standard of care for renal cell carcinoma; however, the cancer can […]

read more

Health-related quality of life for kidney cancer patients on pembrolizumab/lenvatinib

In this video, Dr Bradley McGregor from the Dana-Farber Cancer Institute in the US and Dr Rana McKay from UC San Diego Health discuss the health-related quality of life of renal cell carcinoma (RCC) patients on the pembrolizumab plus lenvatinib combination. The results from the phase 3 CLEAR/KEYNOTE-581 trial with 1069 RCC patients showed significant […]

read more

FDA approves pembrolizumab plus lenvatinib combination for advanced kidney cancer

The US Food and Drug Administration (FDA) has approved the combination of pembrolizumab, an anti-PD-1 immunotherapy, plus lenvatinib, an oral tyrosine kinase inhibitor, for the first-line treatment of people with advanced renal cell carcinoma (RCC). The approval is based on the results from the phase 3 CLEAR/KEYNOTE-581 trial, in which the combination showed significant improvement […]

read more

Lenvatinib plus pembrolizumab in for untreated and previously treated metastatic kidney cancer

Results from a phase Ib/II study looking at lenvatinib plus pembrolizumab for the treatment of metastatic renal cell carcinoma (RCC) showed that there was a response to treatment and the cancer reduced in size (objective response) in 73% of patients who had not received previous medication for their cancer. There were 143 patients in the […]

read more

ASCO 2021: Pembrolizumab plus axitinib continues to improve survival in kidney cancer

The KEYNOTE-426 study of the immune checkpoint inhibitor, pembrolizumab plus the VEGF inhibitor, axitinib for advanced renal cell carcinoma continues to show survival benefits compared with sunitinib as a first treatment after surgery. In this oral presentation from the American Society for Clinical Oncology (ASCO) Annual Meeting, further follow-up data from KEYNOTE-426 over more than […]

read more

ASCO 2021: Health-related quality of life for lenvatinib plus pembrolizumab for advanced kidney cancer

Results from the phase 3 CLEAR study were presented at the American Society for Clinical Oncology (ASCO) Annual Meeting at the weekend. Previous studies have shown that lenvatinib (VEGF inhibitor) used together with pembrolizumab (immune checkpoint inhibitor) resulted in better survival and cancer shrinkage compared to sunitinib when used for patients with advanced renal cell […]

read more

ASCO 2021: Pembrolizumab as adjuvant therapy for kidney cancer

Adjuvant therapy is medication that is given in addition to surgery (nephrectomy) to try to prevent the cancer from coming back. Adjuvant therapy can be used to kill any remaining microscopic cancer cells, or it can control the growth of any remaining cancer. Nephrectomy is the standard of care for renal cell carcinoma (RCC); however, […]

read more

Adjuvant pembrolizumab extends disease-free survival in kidney cancer patients

Interim results from a phase 3 clinical trial called KEYNOTE-564 have shown that pembrolizumab given after nephrectomy (adjuvant pembrolizumab) for intermediate to high risk renal cell carcinoma (RCC) prolonged disease-free survival compared with placebo. Adjuvant pembrolizumab also improved disease-free survival in patients who had surgery to remove metastases. The study included 950 patients with renal […]

read more
Showing 1 to 10 of 58 results
  TOP